Status update regarding the completion of Lumito’s first product

The development of Lumito’s first product (instrument + staining reagent) in digital tissue diagnostics, for analyzing tissue sections stained with the company’s nano-based staining reagents, is entering its final stage prior to launch. The development of the actual instrument is proceeding according to plan, and the first instruments, which are intended for customer validation at reference clinics, are planned for delivery (with CE Mark approval) in April,

Lumito’s staining reagent development partner, RISE, has now announced that work on reagents still is on-going but is expected to be finished during the second quarter.

– RISE's statement entails that our product (instrument + staining reagent) for the reference clinics is now estimated to be ready during the second quarter, not the first as previously disclosed. The notice from RISE is regrettable, but it is of the utmost importance that we maintain a high quality when we supply the reference clinics with our product, says Stefan Nilsson, Lumito's CEO. 

This information is information that Lumito AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on 13 February 2020, at 6:30 PM.


For more information, please contact:
Stefan Nilsson, CEO of Lumito AB (publ) 
Email: sn@lumito.sePlease see also: